by on August 15, 2017. For personal use only. jnm.snmjournals.org Downloaded from ABSTRACT Purpose: Oncolytic virus (OV) therapy has emerged as a novel tool in our therapeutic arsenals for fighting cancer. As a live biological agent, oncolytic virus has the ability to target and selectively amplify at the tumor sites. We have reported that a vaccinia-based OV (Pexa-Vec) has shown good efficacy in pre-clinical models and in clinical trials. In order to give an additional tool to clinicians to allow both treatment of the tumor and improved visualization of tumor margins, we developed new viral based platforms with two specific gene reporters.
. Oncolytic viruses are commonly based on engineered viruses that are attenuated, armed and/or retargeted (4, 5) . Poxvirus, particularly vaccinia virus (VV) has been shown to be a good candidate.
The poxvirus genome can be easily genetically modified to accommodate inserts as large as 25 kb, using strategies that are dependent upon homologous recombination (6) . Using these approaches, poxvirus family members have proven to be valuable vectors for gene therapy in a number of therapeutic applications (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) , and have shown promise as novel vaccines against such diseases as acquired immunodeficiency syndrome (18), malaria (19), tuberculosis (20), and cancer (7, 8, 12, 13) . Oncolytic vaccinia is known to infect a wide range of cells but only productively replicate in cancer cells with a persistent viral gene expression (21-23). Exploiting the vaccinia late promoter for the expression of genes of interest may provide the opportunity to maintain expression of the transgene over several days specifically in the tumor environment where viral replication is favored. Therefore, VV could be the platform of choice to express specific gene(s) that localize to and allow visualization of evolving tumors.
Two genes of potential interest for expression in the vaccinia platform were: 1) the sodium/iodide symporter (NIS) (24) and 2) the Somatostatin receptor type 2 (SSR2) (25). The use of NIS expression has been extensively used for imaging in combination with radiolabeled Technetium-99 or Iodine-131. NIS has been exploited therapeutically in thyroid related disease, and ectopic expression of this gene has also been important to extend the use of radioiodine for non-thyroid tumors (26, 27) . Notably, previous studies reported the use of measles virus as a platform expressing NIS and, research that has led to a current phase 1 clinical trial for ovarian cancer (28). SSR2 is a member of the superfamily of somatostatin receptors whose ligand is the peptide hormone somatostatin (29). Interestingly, somatostatin has also been shown to inhibit proliferation of many solid tumors, notably pancreatic cancer using a somatostatin analog. sandostatin or octreoide acetate has been widely used in treating carcinoid tumors (30).
Here we describe the construction of two new recombinant VV harboring hNIS or hSSR2 as in vivo tumor imaging candidates and as cancer therapeutic candidates. Our data indicate that highlevel expression of hNIS and hSSR2 in recombinant VV from the early promoter leads to lower viral titers. In addition, the late promoter, although considered weaker than the early promoter, led to higher levels of hNIS expression on the membrane of the infected cells. Consequently, the uptake of iodide and technetium is also greatly improved using a late promoter in recombinant vaccinia vectors. Imaging/therapeutic virus candidates were found to preferentially replicate in various tumor sites in vivo and can be clearly mapped using MicroSPECT/CT without affecting normal tissues. hNIS-encoding virus has also been shown effective at killing tumor cells in vivo, suggesting a possible role as a therapeutic agent. Our results strongly suggest that these novel vaccinia recombinants expressing hNIS or hSRR2 may be useful to localize, visualize, follow and treat various types of tumor and warrant further investigation in a clinical setting. 
In vivo GFP detection
VV-infected mice were put into sleep using isoforane. The bioluminescence was detected using a 200 Series IVIS Imager (Xenogen) and Living Image® v2.5 software.
Fluorescence microscopy. To detect hNIS production from recombinant VV, U2OS cells (2x10 5 ) were seeded and infected with virus (MOI=0.01) for two days. The cells were washed (PBS) and fixed (4%paraformaldehyde) for 10min. The cells were treated for 30min with blocking buffer (0.2%Triton X-100, 5% goat serum) and incubated overnight at 4°C (1:100 antihNIS). The cells were washed with PBS, incubated for 30min (Cy3-conjugated goat antirabbit), washed (3x), mounted on a slide. DNA was stained with 1.5µg/mL 4,6-diamidino-2-by on August 15, 2017. For personal use only. jnm.snmjournals.org Downloaded from phenylindole (DAPI). Cell images were captured using a Zeiss Axioplan-2 microscope equipped with Axioview 3.1 software.
Virus DNA extraction, PCR and Sequencing
DNA was extracted from purified virus stocks by adding a lysis buffer (5mM Tris pH8.0, 2.5%Tween-20, 2.5%NP-40, 250mg/mL proteinaseK) followed by incubation at 55°C for 4hr.
Samples were boiled 10min and DNA purified by phenol extraction. Regions spanning the thymidine kinase gene were amplified by PCR and sequenced to confirm the virus harboring the intended inserts.
Western blotting
Cells were infected, washed with PBS and lysed with mammalian cell lysis buffer or ProteoJET 
Micro-SPECT imaging
Images were acquired on a 4-head small-animal SPECT/CT camera (NanoSPECT, Mediso). A 9-hole 1-mm diameter multi-pinhole collimator was attached to each head. For all studies, a spiral CT (45kVp, 500mAs/projection) was acquired to assist with localization of the radiotracer distributions. The expression of NIS was visualized through uptake of 
Animal Care:
All animals were handled in strict accordance with good animal practice as defined by the relevant national and local animal welfare bodies, and all animal work was approved by the appropriate committee (University of Ottawa, Animal Care Committee, ME-220 protocol, Dr.
John Bell).

RESULTS
Recombination of hNIS and hSSR2 with Vaccinia Wyeth strain.
Wyeth VV strain with loss of the Thymidine Kinase (TK) gene were shown to have significantly decreased pathogenicity compared to wild type virus and more specificity to tumor tissues. This vaccinia locus was chosen for insertion of the human sodium iodide symporter (hNIS) or the somatostatin receptor-2 (hSSR2). The target insertion site for hNIS and hSSR2 is shown in a schematic of the shuttle vector generated for recombination into the VV-TK locus ( Figure 1A and 2A). As hNIS and hSSR2 recombinant viruses are intended for imaging the productive infection at tumor sites, late expression of hNIS is more desirable for a stronger expression in the cells. Besides the early and late promoter p7.5, we have also expressed the hNIS and the hSSR2 with a synthetic late promoter p00, and p04. Selected viral plaques are depicted in supplemental Figure 1 and show no obvious difference in term of size compared to parental virus used to make recombinants. After a GFP flow cytometer-based selection, viruses were plaque purified multiple times.
The expression of hNIS from recombinant viruses was determined in both infected cancer cells (Hela) and normal cells (GM38) (Figure 1B-C) . First, VV-hNIS utilizing either the p00 or p04 late promoters shows strong tropism for tumor cells based on the enhanced expression of GFP (Figure 1B) , the higher virus titers ( Figure 1C ) and the enhanced expression of hNIS ( Figure   1D ) in the tumor cell line when compared to normal cells. While specific hNIS expression was confirmed and as expected accordingly to the literature by western blot (Figure 1D ) (32) (33) (34), the functionality of the symporter was validated by measuring the accumulation of iodine-131 or Technetium-99 radioisotopes into the cells (Figure 1E-F) . This accumulation is NIS specific as KClO4 can block the uptake. hNIS driven by late promoters again are found to be more active than expression from the early late p7.5 promoter when cells were infected with the same MOI ( Figure 1E ).
In parallel, expression of hSSR2 from recombinant VV-hSSR2 viral constructs was validated by immunofluorescence ( Figure 2B-C) . Specific staining for SSR2 in infected cells (GFP expressing) confirmed both expression and localization of SSR2 (Figure 2B-C) . Interestingly, using an early/late promoter (p7.5) or a late promoter (p04) changed the localization of SRR2. In fact, aggregation was observed with the early/late promoter and, a more homogenous distribution suggesting a better functionality was observed using a late vaccinia promoter ( Figure 2C ).
Late promoter hNIS encoding virus can infect and lyse cancer cells
hNIS oncolytic virus candidates were tested in vitro and vivo for their ability to spread in Interestingly, we have noted that the signal persisted for at least to 11 days after the initial viral injection (Data not shown). While these studies were initially performed with intratumor delivery of virus, intravenous delivery of virus was also found to be sufficient for in vivo imaging of tumor using microSPECT/CT (Figure 4B) , opening the possibility of using systemic virus delivery to image tumors at remote sites. With the aim to assess the safety profile of using a viral platform expressing NIS receptor, we determined the level of virus replication, human NIS expression and radioactive tracer accumulation in various tissues from tumor-bearing and tumorfree mice (Supplemental Figure 1) . At 24 hrs, 48 hrs, and 72 hrs post virus injection, 99m Tcpertechnetate was injected and normal tissues (including blood, brain, bone, muscle, stomach, bladder, thyroid, ovaries) were harvested from both tumor-free and tumor-bearing mice with the additional tumor tissue harvested from the latter group of mice. A Gamma counter was then used to measure the radiation in each tissue (Supplemental Figure 1A) . Subsequently, portions of all tissues were homogenized and membrane proteins extracted for Western blotting to assay expression of the human NIS protein (Supplemental Figure 1B) . Finally, the remaining portions of the tissues were titered for Vaccinia virus (Supplemental Figure 1C) . As expected, we observed a strong radiation signal in tumor in addition to a strong signal in the few normal tissues in both tumor-free or tumor-bearing mice that are known to express endogenous murine NIS (thyroid, bladder and stomach). Consistent with these finding, the virus was only detected in high amounts in tumor tissues (Supplemental Figure 1C) . This observation matched perfectly with the western blotting, where expression of human NIS was only seen in the tumor tissue. In conclusion, based on tissue viral titres, significant amounts of virus replication occurs primarily in the tumor tissue. This correlates well with our ability to detect the virus encoded human NIS protein only in tumor tissue and with the observation that the only tissues that accumulated the pertechnetate radiotracer, other than tissues known to express endogenous murine NIS, were the tumor tissues.
In parallel, the octreotide radiolabeled with 111 Indium, a drug already in clinic use, was similarly effective for imaging tumor infected with virus candidates expressing hSSR2 ( Figure   4C ). As expected, results mirrored those obtained with hNIS expressing vaccinia and tumor labeling with 99 Tc was observed confirming the potential of this viral technology to be used for both imaging as well as anti-tumor therapeutic.
hNIS encoding virus is able to infect and localize multiple tumors by imaging.
The murine tgMISIIR-Tag, a T-antigen driven ovarian cancer model, makes several foci of tumor development in the ovaries and is an extremely difficult model to cure. We tested vaccinia hNIS viral platform for imaging tumors in this model to assess the potential of this new therapeutic candidate ( Figure 5A) . Interestingly, the systemic injection of the VV-hNIs virus revealed clear imaging of multiple tumor nodules in the tumor bearing mice in vivo, using 99 Tc.
Replication of vaccinia in this model was evident by imaging of GFP expression in excised ovarian tumors ( Figure 5C ). A survival study using the same ovarian tumor model ( Figure 5B) showed enhanced survival of mice that received the hNIS virus with I131 when compared to I131 treatment alone. Together, these data strongly suggest 1) the potential clinical use of viruses expressing symporter in combination with radioisotopes to localize and visualize tumor growth and, 2) the direct therapeutic potential of using viral platforms expressing symporter for treating various types of cancers.
Finally, using HT29 tumor, we examined the ability of VV-hNIS and VV-hSRR2 to replicate and also to accumulate injected radioisotopes in the tumor of a single animal ( Figure 6 ).
Four days after injections of viruses, technetium and iodide radioisotope were co-injected intraperitoneal ( 111 In) or intra-venous ( 99 Tc) and tracer were followed by microSPECT/CT. Result shows both radioisotopes accumulation in the tumor implantation suggesting that hNIS and hSRR2 encoding viruses can both be used simultaneously for imaging.
DISCUSSION
In this study, we show the potential use of VV expressing two different genes, NIS symporter and the SSR2 receptor in the aim of visualizing and treating tumor. Using microSPECT/CT imaging system we were able to clearly visualize and localize tumor in various mouse models.
Using this recombinant vaccinia expression platform, systemic administration of virus and subsequently radioisotopes led to accumulation of isotope in the tumor bed and improved survival in an ovarian cancer model. Poxviruses continue to be important therapeutics for the prevention and treatment of human diseases. Vaccinia application for the eradication of smallpox has been one of the most important medical advances in human history providing to the scientific and medical community strong data on the safety profile of the virus. A variety of poxvirus based vaccine vectors have been developed for human infectious diseases and as agents for the treatment of cancer. This characteristic gives us the opportunity to combine two desirable effects: a cancer therapeutic and a cancer tool for tumor localization. The lytic ability of the platform has been described several times in various pre-clinical models but also in clinical trials. An important feature of this specific vaccinia viral platform is its strong ability to image the tumor after systemic injections, making this platform a very attractive prospect for mapping and imaging tumor in patients with metastatic disease. Also, due to its large genome and to its slow replication, as a viral platform, vaccinia can uniquely replicate in the tumor over the course of several days after systemic injection, giving the opportunity for recombinant gene to be expressed during a long period of time. We also show that the choice of vaccinia promoters regulating the expression of the transgenes is crucial. In fact, a late promoter, in both platforms expressing hNIS or hSSR2, is clearly more advantageous for maintained strong expression in tumor cells when compared to an early/late promoter. Moreover, we also observe that the SSR2 localization is optimal using late promoter. The radiotracer concentration taken up in tumor nodules is critical for capturing a strong enough signal for imaging using the microSPECT/CT and is obviously extremely dependent on the level of expression of the symporter/receptor. Strongest and most functional expression of the symporter and receptor in vivo was observed when we use late vaccinia promotor p00 or p04. Route of injection of therapeutic agent can be a source of great debate; vaccinia virus expressing specific reporter genes can help in the decision and contribute to a better success in the following clinical trials when used as stand-alone or in combination with specific anticancer treatment such as checkpoint inhibitors.
CONCLUSION
Here we report the use of two new vaccinia-based viruses expressing two different imaging genes for tumor visualization and treatment. Both platforms, with their respective radiolabelled counterparts, can be used independently or together offering unique opportunities to diagnose suspected cancer, visualize multiple metastasis with high quality microSPECT/CT imaging and, to provide a treatment through the use of the oncolytic viral platform activating multiple mechanism of action against tumor. 
